An autosomal dominant genetic test looks for a disease-causing change in a gene where one altered copy can be enough to affect health. The result may confirm a suspected diagnosis, estimate future disease risk, or show whether a known family variant was inherited. A positive result often means each biological child has a 50% chance of inheriting the same variant, but it does not always predict the age symptoms will begin or how severe they will be. Some dominant conditions have reduced penetrance, variable symptoms, or a new variant that was not present in either parent. The most informative testing plan usually starts with an affected relative whenever possible and uses a clinical laboratory that can detect the relevant types of DNA changes. Results should be interpreted with the person’s symptoms, age, medical history, and family history rather than treated as a stand-alone answer.
- One altered gene copy may be enough: Autosomal dominant conditions usually occur when a pathogenic variant affects one of the two copies of a gene on a non-sex chromosome.
- The usual child risk is 50% per pregnancy: An affected person with one altered copy has a 1-in-2 chance of passing it on each time, regardless of previous children’s results.
- A positive result does not always predict symptoms: Penetrance, age of onset, and severity can differ even among relatives with the same variant.
- A negative result is most reassuring when a family variant is known: Testing negative for that exact variant is different from having an unrevealing broad panel.
- A VUS is not a diagnosis: A variant of uncertain significance should not usually guide major medical or reproductive decisions.
- Testing an affected relative first often gives the clearest answer: It helps identify the familial variant that other relatives can then test for directly.
Table of Contents
- What an Autosomal Dominant Genetic Test Is
- How Autosomal Dominant Inheritance Works
- Who May Benefit From Testing
- How Testing Is Done
- Understanding Positive, Negative, and Uncertain Results
- Why Inheritance Risk Is Not Always Simple
- Family Testing and Reproductive Choices
- Next Steps After Results
What an Autosomal Dominant Genetic Test Is
An autosomal dominant genetic test is not one single laboratory test. It is a clinical testing approach used when a condition can result from a harmful variant in just one copy of a gene located on an autosome, one of chromosomes 1 through 22. People usually have two copies of each autosomal gene, one inherited from each biological parent.
The test may examine one gene, a group of genes, or a much larger portion of the genome. The best method depends on the condition being considered and the types of variants known to cause it. A targeted test may look only for a specific familial variant. A single-gene genetic test may sequence one gene and check for deletions or duplications. A multigene panel may be more appropriate when several genes can cause overlapping symptoms, such as inherited cardiomyopathy, epilepsy, connective tissue disease, or hereditary cancer.
Autosomal dominant testing can serve several purposes:
- Diagnostic testing investigates symptoms or clinical findings that may have a genetic cause.
- Predictive testing estimates the chance of developing a condition later, before symptoms appear.
- Presymptomatic testing looks for a variant expected to cause disease eventually, although onset may vary.
- Familial variant testing checks whether a relative inherited a specific variant already identified in the family.
- Prenatal or preimplantation testing determines whether a pregnancy or embryo inherited a known familial variant.
Many well-known conditions can follow an autosomal dominant pattern, including Marfan syndrome, neurofibromatosis type 1, Huntington disease, familial hypercholesterolemia, autosomal dominant polycystic kidney disease, and several hereditary cancer syndromes. The same inheritance label does not mean these conditions have the same severity, age of onset, treatment, or likelihood of symptoms.
A medical result should also distinguish germline testing from tumor-only testing. A germline variant is generally present throughout the body and can be inherited. A variant found only in tumor cells arose during life and is not automatically inherited. When a tumor report suggests a possible inherited change, confirmatory germline genetic testing may be needed using blood, saliva, or another non-tumor sample.
How Autosomal Dominant Inheritance Works
In the classic situation, a person with an autosomal dominant condition has one altered gene copy and one working copy. This is called heterozygosity. If that person has a child with someone who does not carry a disease-causing variant in the same gene, each pregnancy has two equally likely possibilities: the child inherits the altered copy, or the child inherits the working copy.
The risk is 50% for every pregnancy. It is not 50% of the family overall, and previous outcomes do not change the next pregnancy’s probability. A parent could have several children who all inherit the variant, several who do not, or any combination.
| Possible result for each child | Chance | What it usually means |
|---|---|---|
| Inherits the pathogenic variant | 50% | May have the condition or increased disease risk, depending on penetrance and age |
| Does not inherit the pathogenic variant | 50% | Will not pass that specific familial variant to future children |
Because the gene is on an autosome, people of any sex generally have the same chance of inheriting and passing on the variant. Father-to-son transmission can occur, which helps distinguish autosomal dominant inheritance from X-linked inheritance in some pedigrees.
A family tree may show affected people in successive generations, sometimes called vertical transmission. However, real families do not always display a textbook pattern. The family may be small, relatives may be young, records may be incomplete, or some carriers may have mild or no recognized symptoms. A variant can also arise de novo, meaning it is new in the tested person rather than inherited from either parent.
When a de novo pathogenic variant is confirmed, the person who carries it can still pass it to biological children with the usual 50% probability. The recurrence risk for the person’s siblings is often low, but it is not always zero because a parent may have germline mosaicism, in which the variant is present in some egg or sperm cells but not detectable in a routine blood sample.
Rarely, both parents carry pathogenic variants in the same dominant gene, or a person has pathogenic variants in both copies. The outcome depends heavily on the gene. Some two-copy combinations cause a more severe disorder, a different clinical condition, pregnancy loss, or no viable pregnancy. These situations require gene-specific counseling rather than a simple Punnett-square estimate.
Who May Benefit From Testing
Testing may be useful when a person’s medical or family history suggests a dominant condition and the result could clarify diagnosis, screening, treatment, or family risk. Common reasons include:
- A parent, sibling, or child has a known pathogenic or likely pathogenic variant.
- The same condition appears in multiple generations.
- Several close relatives have related findings, such as early heart disease, aortic enlargement, kidney cysts, unusual cancers, or progressive neurologic symptoms.
- A condition occurred at an unusually young age.
- A clinician finds a distinctive combination of features associated with a known syndrome.
- A person wants reproductive information about a documented familial variant.
- Tumor testing identifies a variant that may also be germline.
Whenever possible, testing should begin with a relative who clearly has the suspected condition. This approach has a higher chance of finding the family’s causal variant. Once a pathogenic variant is identified, relatives can have a focused familial variant genetic test, which is usually faster, less expensive, and easier to interpret than broad testing.
Testing an unaffected person first may still be reasonable when no affected relative is available. However, a negative result may be uninformative. It could mean the family’s condition is not genetic, the responsible gene was not included, the laboratory method could not detect the variant, the current evidence is insufficient, or the person simply did not inherit the family’s unknown variant.
Testing children requires special judgment. It is generally most appropriate when a result would change care during childhood, such as surveillance, treatment, activity guidance, or emergency planning. Predictive testing for a condition that begins only in adulthood may be deferred so the individual can decide after reaching adulthood. Exceptions depend on the disease, family circumstances, available prevention, and professional guidance.
Before testing, the clinician or genetics professional should define the clinical question. “Does this person have a pathogenic FBN1 variant consistent with Marfan syndrome?” is more useful than “Do a DNA test.” The question determines which genes, variant types, and laboratory methods must be included.
How Testing Is Done
Most germline tests use blood or saliva. A cheek swab may also work. The sample source usually does not change the inherited DNA result, although blood may be preferred when sample quality, mosaicism, or technical confirmation is important.
The laboratory method must match the suspected genetic change. DNA sequencing reads the order of DNA bases and can detect many small substitutions and short insertions or deletions. Deletion-and-duplication analysis looks for missing or extra pieces of a gene. Some conditions require specialized methods for repeat expansions, methylation changes, structural rearrangements, or low-level mosaicism. A sequencing-only test may miss variants that another method would find.
Testing options commonly include:
| Test design | Best suited for | Main limitation |
|---|---|---|
| Targeted familial variant test | A known pathogenic variant in the family | Does not search broadly for other variants |
| Single-gene test | A highly specific condition linked mainly to one gene | May miss another gene causing a similar presentation |
| Multigene panel | Conditions with overlapping features or several possible genes | More likely to find uncertain or unexpected variants |
| Exome or genome sequencing | Complex, unexplained, or genetically heterogeneous cases | May not detect every repeat, methylation change, or structural variant |
Turnaround time ranges from days for an urgent targeted test to several weeks or months for broad sequencing and complex interpretation. The report should identify the gene, the exact variant, the classification, the inheritance model, the laboratory’s methods and limitations, and any recommended follow-up.
Clinical laboratories typically classify variants as pathogenic, likely pathogenic, uncertain significance, likely benign, or benign. Classification depends on several lines of evidence, such as how common the variant is in the population, whether it disrupts gene function, whether it appears with disease in families, whether it occurred de novo, and whether published cases or experiments support a harmful effect.
A laboratory result is not necessarily permanent. Evidence can change, and a genetic variant classification may be updated. Patients should keep a copy of the original report, not just a summary in a clinic note, because the exact gene and variant notation are needed for family testing and future reinterpretation.
Understanding Positive, Negative, and Uncertain Results
A result should answer two separate questions: Was a relevant variant found? and How strongly does that variant explain the person’s health risk or symptoms? The same laboratory category can have different implications depending on why testing was ordered.
Positive or likely positive result
A positive result usually means the laboratory identified a pathogenic or likely pathogenic variant consistent with an autosomal dominant condition. In a symptomatic person, it may confirm or strongly support a diagnosis. In an unaffected person, it may show increased future risk or an expectation of later disease, depending on the condition.
A positive result can influence:
- Screening age and frequency
- Preventive medication or surgery
- Treatment selection
- Avoidance of specific medications or activities
- Specialist referrals
- Emergency precautions
- Testing for biological relatives
- Pregnancy and embryo-testing options
Positive does not mean that symptoms are inevitable in every condition. It also does not automatically reveal when disease will begin or how severe it will be. The report must be combined with gene-specific penetrance data, the person’s age, clinical findings, and family history.
True negative result
A true negative occurs when a pathogenic familial variant is already known and the tested relative does not carry it. This is usually the clearest negative outcome. The person generally does not have the increased risk caused by that specific variant and cannot pass that variant to biological children.
A true negative does not erase unrelated health risks. The person still needs ordinary care based on age, medical history, lifestyle, and any other family conditions.
Uninformative negative result
An uninformative negative means testing did not find an explanation, but no known familial variant was available to rule out. This does not prove that the condition is absent or non-genetic. Current tests may not cover the causal gene or variant type, and scientific knowledge may not yet connect the relevant change with disease.
Medical management may still follow the person’s symptoms and family history. Reanalysis, a broader panel, exome or genome sequencing, RNA studies, or testing another affected relative may later provide an answer.
Variant of uncertain significance
A VUS means a DNA change was found, but the available evidence cannot show whether it causes disease. It should not be treated as a positive diagnosis. Major interventions generally should not be based on a VUS alone, and unaffected relatives should not usually undergo predictive testing for it unless a genetics team recommends family studies to help clarify classification.
Many uncertain variants are later reclassified as benign or likely benign; some become pathogenic or likely pathogenic. The laboratory may issue an amended report, but notification practices vary. Periodic review is reasonable, especially if the result could change medical care.
Unexpected or secondary finding
Broad sequencing can reveal a pathogenic variant unrelated to the original reason for testing. Before testing, consent should address whether such findings may be reported. A secondary finding may have important health implications, but it requires confirmation and condition-specific interpretation.
Why Inheritance Risk Is Not Always Simple
The 50% transmission rule describes whether a heterozygous parent passes the variant. It does not fully describe whether the child will develop symptoms, at what age, or with what severity.
Penetrance is the proportion of people with a variant who develop the associated feature or condition. With complete penetrance, nearly everyone who carries the variant develops the expected phenotype. With reduced penetrance, some carriers remain unaffected. A person who appears healthy can therefore carry and transmit a dominant variant.
Variable expressivity means carriers can have different symptoms or degrees of severity. One relative may have mild findings, while another with the same variant has serious complications. Differences can reflect age, other genes, environmental factors, sex-related biology, medical care, chance, or mechanisms that are not fully understood.
Age-dependent penetrance means risk changes over time. A young adult who carries a variant linked to a later-onset disorder may have no symptoms yet. A family tree can look as though the condition skipped a generation when relatives died young from unrelated causes or have not reached the usual age of onset.
Mosaicism occurs when not all cells carry the same genetic change. A parent with low-level mosaicism may have mild or absent symptoms but still pass the variant. A blood test can miss a variant that is confined to other tissues or present below the assay’s detection threshold.
De novo variants explain why a dominant condition may appear in a child whose parents are unaffected. Parental testing can help determine whether the variant was inherited, arose de novo, or may reflect mosaicism. Confirming biological relationships may be relevant to the laboratory’s interpretation, and this sensitive issue should be handled respectfully.
Gene-specific mechanisms can also alter the usual assumptions. Some variants increase gene activity, some reduce it, and others interfere with the working copy. Different variants in the same gene may cause distinct disorders. A result is meaningful only when the variant’s mechanism matches the known gene-disease relationship.
Risk figures may be further adjusted by reproductive partner status, especially if variants in both copies can cause a separate recessive or severe condition. The broad label “autosomal dominant” is therefore a starting point, not the entire risk assessment.
Family Testing and Reproductive Choices
A confirmed pathogenic variant has implications beyond the person tested. First-degree relatives—biological parents, siblings, and children—often have up to a 50% chance of carrying the same inherited variant. More distant relatives may also be at risk through the side of the family where the variant originated.
Cascade testing is the stepwise testing of relatives for a known familial variant. It is most efficient when the family shares the exact laboratory report. A verbal description such as “the cancer gene was positive” is not precise enough. Relatives need the gene name, variant notation, and classification so their laboratory can order the correct test.
Families vary in how they communicate genetic information. A clinic may provide a family letter that explains the finding without disclosing unnecessary medical details. The tested person generally controls whether to share the result, although clinicians can discuss serious and preventable risks, privacy rules, and practical ways to notify relatives.
People planning a pregnancy may consider several options:
- Conceiving without genetic testing
- Prenatal diagnosis using chorionic villus sampling or amniocentesis
- In vitro fertilization with preimplantation genetic testing for the familial variant
- Donor egg, donor sperm, or donor embryo
- Adoption
- Choosing not to have children
These are personal choices rather than required responses to a positive result. A 50% chance of inheriting a variant is not the same as a 50% chance of severe disease when penetrance or severity varies. Reproductive counseling should explain both transmission probability and expected clinical outcomes.
Testing during pregnancy should be planned carefully. A fetal result may show whether the variant is present but may not predict severity, age of onset, or all clinical features. Laboratories usually need documentation of the familial variant before developing or performing a targeted prenatal assay.
Next Steps After Results
The most useful next step is a condition-specific review with the ordering clinician, a medical geneticist, or a genetic counselor. Bring the full report and a three-generation family history if available.
After a positive result, the care plan may include:
- Confirming that the variant and the person’s findings fit the same condition.
- Arranging baseline evaluations for organs that may be affected.
- Starting surveillance at the recommended age and interval.
- Discussing treatment, prevention, or emergency precautions.
- Identifying relatives who may benefit from targeted testing.
- Recording the result in a durable, accessible part of the medical record.
- Revisiting the plan as guidelines or variant knowledge change.
After a negative result, ask whether it is a true negative or an uninformative negative. Also ask what the test could not detect, whether an affected relative should be tested, and whether future reanalysis is available. A negative report should not override strong clinical evidence when the test’s sensitivity is incomplete.
After a VUS, continue care based on symptoms and family history rather than assuming the variant is harmful. Ask whether the laboratory offers reclassification updates and whether testing selected relatives could provide useful evidence. Do not use a VUS alone to label healthy relatives as affected or unaffected.
Direct-to-consumer testing may not provide the same gene coverage, technical confirmation, or clinical interpretation as diagnostic testing. A medically important result from a consumer test should generally be confirmed in a qualified clinical laboratory before health decisions are made.
Genetic information can also affect emotions, family relationships, privacy concerns, and insurance planning. In the United States, federal protections limit certain uses of genetic information in health insurance and employment, but they do not cover every form of insurance. Rules vary by country and can change, so people with concerns should seek current, location-specific guidance before testing.
The result is most valuable when it leads to a clear plan. That may be increased surveillance, reassurance after a true negative, targeted testing for relatives, or recognition that present-day testing has not yet solved the family’s medical question.
References
- Genetics, Autosomal Dominant 2023 (Review)
- Autosomal dominant 2024 (Official)
- Genetic Testing Fact Sheet 2024 (Official)
- DNA Sequencing Fact Sheet 2023 (Official)
- Genetic Testing for Hereditary Breast and Ovarian Cancer 2024 (Official)
- What are reduced penetrance and variable expressivity? 2021 (Official)
Disclaimer
This article provides general education about autosomal dominant genetic testing and does not interpret any individual result. Test selection, risk estimates, and medical follow-up depend on the specific gene, variant, condition, personal history, and family history; review results with a qualified genetics professional or clinician.
